A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (LBP)
A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 as Compared to RLD2401 in Chronic Low-Back Pain Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Jee Won Shon
- Phone Number: 82-2-410-9037
- Email: jeewon.shon@hanmi.co.kr
Study Locations
-
-
Seoul
-
Seoul, Seoul, South Korea, 04763
- Hanyang University Seoul Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Chronic low back pain ≥3 months in duration
- Quebec Task Force in Spinal Disorders class 1 or 2
Male or female ≥ 19 years of age with following criteria:
- ≥ 50 years
- 19~ 49 years with history of gastric or duodenal ulcers within the past 5 years
- Low back pain disease condition expected to require daily NSAIDs therapy for at least 12 weeks
- VAS ≥ 40 (at Visit 2) (If there are any treatment history to affect the efficacy evaluation of low back pain, VAS after washout period have to meet the criteria; 20% over baseline VAS or change from baseline VAS ≥10)
Exclusion Criteria:
- Diagnosed with certain serious diseases that may be secondary causes of Low back pain (e.g., tumors, infectious diseases, gout, etc.)
- Clinically significant neurological disease or low back pain due to trauma (e.g. spinal fracture) within the past 6 months
- Invasive procedures (using corticosteroids) in the lumbar region within the past 3 months or surgical intervention within the past 6 months or need to such interventions during the study
- History of non-drug treatment of the lumbar region (e.g., physical therapy) for the purpose of alleviating low back pain within 7 days prior to the screening visit.
- Active gastritis, inflammatory bowel syndrome, peptic ulcer or any history of gastrointestinal bleeding duodenal ulceration within the past 3 months
- Patients with history of platelet-related disease or bleeding disorder within the past 6 months or who are taking anti-coagulants
- Patients with ischemic heart disease or severe cerebrovascular disease within the past 6 months
- Bronchial asthma or Uncontrolled Diabete Mellitus or Hypertension
- Use of peptic ulcer treatment (H2-blockers, PPI, PCAB series or Misoprostol), psychotropic drugs, narcotic analgesics or systemic corticosteroids within past 4 weeks
- Severe renal dysfunction (Creatinine clearance ≥ 30mL/min ) or Severe liver dysfunction (AST or AST ≥ 3 x UNL)
- History of malignant tumors within past 5 years
- Positive to pregnancy test, nursing mother, intention on pregnancy
- Considered by investigator as not appropriate to participate in the study with other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental 1
Take HCP1004 twice daily for 12 weeks orally.
|
Test Drug
|
|
Active Comparator: Active Comparator
Take RLD2401 twice daily for 12 weeks orally.
|
Reference drug
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in VAS
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in VAS(Visual Analog Scale)
Time Frame: 8 weeks, 12 weeks
|
8 weeks, 12 weeks
|
|
Change from baseline in ODI(Oswestry Disability Index) Score
Time Frame: 4 weeks, 8 weeks, 12 weeks
|
4 weeks, 8 weeks, 12 weeks
|
|
Change from baseline in EQ-5D Score
Time Frame: 4 weeks, 8 weeks, 12 weeks
|
4 weeks, 8 weeks, 12 weeks
|
|
Change from baseline in GSRS(Gastrointestinal Symptom-Rating Scale) Score
Time Frame: 4 weeks, 8 weeks, 12 weeks
|
4 weeks, 8 weeks, 12 weeks
|
|
Usage of rescue medicine
Time Frame: 4 weeks, 8 weeks, 12 weeks
|
4 weeks, 8 weeks, 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HM-NEON-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.